LIPOCINE INC (LPCN) Fundamental Analysis & Valuation
NASDAQ:LPCN • US53630X2036
Current stock price
7.15 USD
-0.25 (-3.38%)
Last:
This LPCN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. LPCN Profitability Analysis
1.1 Basic Checks
- LPCN had negative earnings in the past year.
- LPCN had a negative operating cash flow in the past year.
- In the past 5 years LPCN reported 4 times negative net income.
- LPCN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -56.61%, LPCN is doing worse than 65.28% of the companies in the same industry.
- With a Return On Equity value of -66.50%, LPCN perfoms like the industry average, outperforming 43.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.61% | ||
| ROE | -66.5% | ||
| ROIC | N/A |
ROA(3y)-42.56%
ROA(5y)-31.51%
ROE(3y)-48.91%
ROE(5y)-35.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LPCN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. LPCN Health Analysis
2.1 Basic Checks
- LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for LPCN has been increased compared to 1 year ago.
- Compared to 5 years ago, LPCN has more shares outstanding
- LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -5.74, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -5.74, LPCN is not doing good in the industry: 63.21% of the companies in the same industry are doing better.
- LPCN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.74 |
ROIC/WACCN/A
WACC9.53%
2.3 Liquidity
- A Current Ratio of 6.68 indicates that LPCN has no problem at all paying its short term obligations.
- LPCN's Current ratio of 6.68 is fine compared to the rest of the industry. LPCN outperforms 72.02% of its industry peers.
- LPCN has a Quick Ratio of 6.68. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of LPCN (6.68) is better than 72.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.68 | ||
| Quick Ratio | 6.68 |
3. LPCN Growth Analysis
3.1 Past
- LPCN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -214.94%.
- The Revenue for LPCN has decreased by -82.35% in the past year. This is quite bad
- Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 58.12% on average per year.
EPS 1Y (TTM)-214.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.58%
Revenue 1Y (TTM)-82.35%
Revenue growth 3Y58.12%
Revenue growth 5YN/A
Sales Q2Q%-67.17%
3.2 Future
- The Earnings Per Share is expected to grow by 18.11% on average over the next years. This is quite good.
- Based on estimates for the next years, LPCN will show a very strong growth in Revenue. The Revenue will grow by 145.40% on average per year.
EPS Next Y-4.31%
EPS Next 2Y18.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-32.9%
Revenue Next 2Y8.18%
Revenue Next 3Y38.51%
Revenue Next 5Y145.4%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. LPCN Valuation Analysis
4.1 Price/Earnings Ratio
- LPCN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year LPCN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- LPCN's earnings are expected to grow with 18.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.11%
EPS Next 3YN/A
5. LPCN Dividend Analysis
5.1 Amount
- LPCN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
LPCN Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:LPCN (3/27/2026, 8:00:00 PM)
7.15
-0.25 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10 2026-03-10/bmo
Earnings (Next)05-06 2026-05-06
Inst Owners29.41%
Inst Owner Change207.95%
Ins Owners2.84%
Ins Owner Change0%
Market Cap52.20M
Revenue(TTM)1.98M
Net Income(TTM)-9.63M
Analysts82.5
Price Target13.26 (85.45%)
Short Float %2.62%
Short Ratio0.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.69%
Min EPS beat(2)-7.12%
Max EPS beat(2)32.5%
EPS beat(4)2
Avg EPS beat(4)6.71%
Min EPS beat(4)-7.12%
Max EPS beat(4)32.5%
EPS beat(8)6
Avg EPS beat(8)102.92%
EPS beat(12)7
Avg EPS beat(12)55.58%
EPS beat(16)10
Avg EPS beat(16)38.19%
Revenue beat(2)1
Avg Revenue beat(2)407.97%
Min Revenue beat(2)-52.63%
Max Revenue beat(2)868.56%
Revenue beat(4)2
Avg Revenue beat(4)227.14%
Min Revenue beat(4)-74.1%
Max Revenue beat(4)868.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.54%
PT rev (3m)89.09%
EPS NQ rev (1m)11.67%
EPS NQ rev (3m)11.67%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 26.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.61 | ||
| P/tB | 3.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.77
EYN/A
EPS(NY)-1.85
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.27
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.61% | ||
| ROE | -66.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.56%
ROA(5y)-31.51%
ROE(3y)-48.91%
ROE(5y)-35.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.68 | ||
| Quick Ratio | 6.68 | ||
| Altman-Z | -5.74 |
F-Score1
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-214.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.58%
EPS Next Y-4.31%
EPS Next 2Y18.11%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-82.35%
Revenue growth 3Y58.12%
Revenue growth 5YN/A
Sales Q2Q%-67.17%
Revenue Next Year-32.9%
Revenue Next 2Y8.18%
Revenue Next 3Y38.51%
Revenue Next 5Y145.4%
EBIT growth 1Y-800.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-644.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-699.27%
OCF growth 3YN/A
OCF growth 5YN/A
LIPOCINE INC / LPCN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to LPCN.
What is the valuation status of LIPOCINE INC (LPCN) stock?
ChartMill assigns a valuation rating of 0 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.
What is the profitability of LPCN stock?
LIPOCINE INC (LPCN) has a profitability rating of 0 / 10.
How financially healthy is LIPOCINE INC?
The financial health rating of LIPOCINE INC (LPCN) is 6 / 10.